1AUFEDNBLATTEN R, BOLHIN M H, HELLS'FROM H, et al. A process for preparing[ 1S-[ 1α,2α,3β-( 1 S,2S) -5β]] -3- [ 7-[ 2-( 3,4-difluorophenyl ) -cyclopropylamino ] -5-( propy- lthil)-3H-1, 2, 3-triazolo [ 4, 5-d] pyrimidin-3-yl ]-5-( 2- hydroxyethoxy) cyclopentane-1,2-diol and to its intermedi- ates :WO,2010030224 [ P]. 2010 -03 - 18.
2RAO T ,ZHANG C. Cyclopropyl modulators of P2Y12 recep- tor:WO,2011017108 [ P] .2011 -02 - 10.
3TANTRY U S,BLIDEN K P,GURBEL P A. AZD6140[ J]. Exp Opin Invest Drugs,2007,16 ( 2 ) : 225 - 229.
4HUSTED S, EMANUELSSON H, HEPTINSTALL S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin [ J ]. Eur Heart J, 2006,27 ( 9 ) : 1038 - 1047.
7Terpening C. Clopidogrel: a pharmacogenomic perspective on its use in coronary artery diseas[J]. Clinical Medicine Insights Cardi- ology, 2010, 4(4) : 117 - 128.
8Anderson CD, Biffi A, Greenberg SM, et al. Personalized ap- proaches to clopidogrel therapy: are we there yet[J ]. Stroke, 2010, 41(12) :2 997- 3 002.
9Nguyen TA, Diodati JG, Pharand C. Resistance to elopidogreh a review of the evidence[ J ]. Journal of the American College of Car- diology, 2005, 45(8) : 1 157 - 1 164.
